GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (GREY:PSTTF) » Definitions » Gross Profit

Prescient Therapeutics (Prescient Therapeutics) Gross Profit : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Prescient Therapeutics Gross Profit?

Prescient Therapeutics's gross profit for the six months ended in Dec. 2023 was $0.00 Mil. Prescient Therapeutics's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Prescient Therapeutics's gross profit for the six months ended in Dec. 2023 was $0.00 Mil. Prescient Therapeutics's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Prescient Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

Prescient Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Prescient Therapeutics Gross Profit Historical Data

The historical data trend for Prescient Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Gross Profit Chart

Prescient Therapeutics Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Prescient Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Prescient Therapeutics's Gross Profit

For the Biotechnology subindustry, Prescient Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prescient Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's Gross Profit falls into.



Prescient Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Prescient Therapeutics's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as

Gross Profit (A: Jun. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Prescient Therapeutics's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Prescient Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Prescient Therapeutics  (GREY:PSTTF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Prescient Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Prescient Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Prescient Therapeutics (Prescient Therapeutics) Business Description

Traded in Other Exchanges
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.